Page 184 - அமெரிக்கன் கல்லூரி ஆஃப் மகப்பேறியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Criticized for Lifting In-Person Requirement to Receive Abortion Drug April 15, 2021 WASHINGTON (CNS) The decision by the acting commissioner of the U.S. Food and Drug Administration to suspend enforcement of the agency’s in-person prescribing requirement for the abortion drug endangers women’s health and possibly their lives, pro-life leaders said. On April 12, Dr. Janet Woodcock said the FDA will “exercise enforcement discretion” regarding its own requirement that is part of the risk management program for mifepristone as long as President Joe Biden’s declaration of a public health emergency for COVID-19 remains in place. A box of the RU-486 drug, an abortion pill known generically as mifepristone and by its brand name Mifeprex, is seen in an undated handout photo. (Photo: CNS/Danco Laboratories handout via Reuters)

United statesChristina francisJanet woodcockJoe bidenTheodore chuangUs supreme courtAmerican college of obstetriciansUs department of healthDrug administrationAmerican association of proPresident joe bidenDanco laboratoriesAmerican associationLife actionJudge theodore chuangAmerican college